Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01399593
First received: July 19, 2011
Last updated: July 13, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)